Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Precision Antibody, SAT complete SBIR contract for antibodies
December 2014
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

COLUMBIA, Md.—Precision Antibody, together with SISCAPA Assay Technologies (SAT), recently completed a Phase 1 SBIR contract from the National Cancer Institute to engineer high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/quantification assays. Using its Affinity Boost, SMART Fusion and SeleKDt technologies, Precision Antibody developed mouse monoclonal antibodies to be used as reagents for SISCAPA technology. SAT then screened the antibody candidates and selected the best ones for use in SISCAPA applications. SAT’s SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) technology enables targeted protein quantitation, combining antibody-based peptide enrichment with quantitative mass spectrometry.
 
“Precision Antibody continues to push the boundaries of monoclonal antibody development,” Leigh Anderson, chief scientific officer of SAT, noted in a statement. “We are excited to work with Dr. Jun Hayashi and his team as they develop the next generation of high-affinity, renewable cancer antibody reagents.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.